"Amgen (as expected) filed suit against Coherus claiming violations of the Neulasta Patent '707 (purification process).", the firm's analyst wrote.
A number of other equities analysts have also recently issued reports on the stock.
02/01/2017 - Coherus BioSciences, Inc. had its " rating reiterated by analysts at Robert W. Baird. Looking at the stock's movement on the chart, Coherus Biosciences, Inc. recorded a 52-week high of $31.98. Zacks Investment Research upgraded Coherus Biosciences from a "hold" rating to a "buy" rating and set a $26.00 price objective on the stock in a research note on Tuesday, February 14th. BMO Capital Markets started coverage on shares of Coherus Biosciences in a research note on Friday, May 5th. Further, analysts have a 12 month target price of $5.72 on company shares. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold.
Trump doesn't want to be president, he wants to be emperor
Trump said an agreement struck with China will allow the U.S.to sell its beef and other major products to that country once again. Trump abruptly fired Comey on Tuesday and later said Comey was a "showboat" and "grandstander" who was not doing a good job.
11/28/2016 - Standpoint Research began new coverage on Coherus BioSciences, Inc. giving the company a "speculative buy" rating.
The share price of the company (CHRS) was up +2.94%, with a high of 24.50 during the day and the volume of Coherus BioSciences, Inc. shares traded was 984966. The firm has a 50 day moving average price of $20.18 and a 200 day moving average price of $24.52. This company shares are 14.09% off its target price of $27.13 and the current market capitalization stands at $18.05B.
Coherus Biosciences (NASDAQ:CHRS) last announced its earnings results on Monday, May 8th. The biotechnology company reported ($1.54) EPS for the quarter, meeting analysts' consensus estimates of ($1.54). Given that its average daily volume over the 30 days has been 0.48 million shares a day, this signifies a pretty significant change over the norm. Equities research analysts expect that Coherus Biosciences will post ($5.13) EPS for the current year. If you are accessing this story on another domain, it was stolen and republished in violation of global copyright and trademark legislation. The correct version of this story can be viewed at https://sportsperspectives.com/2017/05/16/coherus-biosciences-chrs-getting-somewhat-positive-media-coverage-analysis-shows-updated-updated-updated.html. A simple moving average (SMA) is an arithmetic moving average calculated by adding the closing price of the security for a number of time periods and then dividing this total by the number of time periods. The sale was disclosed in a filing with the SEC, which is available at this link. Pictet Asset Management Ltd. boosted its stake in shares of Coherus Biosciences by 0.3% in the first quarter.
Snapchat co-founders lose $2 billion after poor Q1
In other news, insider Alan C. Herman sold 11,333 shares of the company's stock in a transaction on Monday, April 3rd. Finally, Tudor Investment Corp Et Al increased its position in shares of Coherus Biosciences by 34.9% in the fourth quarter. Legal & General Group Plc now owns 8,295 shares of the biotechnology company's stock valued at $173,000 after buying an additional 1,137 shares during the last quarter.
Coherus BioScience (CHRS) is rising Wednesday, after a patent trial ruled in its favor of and against AbbVie (ABBV) in a lawsuit over Humira, the rheumatoid arthritis drug that accounts for almost two-thirds of AbbVie's sales. State Board of Administration of Florida Retirement System now owns 14,589 shares of the biotechnology company's stock worth $411,000 after buying an additional 130 shares during the last quarter. Finally, Croft Leominster Inc. purchased a new stake in shares of Coherus Biosciences during the third quarter valued at $401,000. Rock Springs Capital Management LP now owns 467,500 shares of the biotechnology company's stock worth $12,520,000 after buying an additional 67,500 shares in the last quarter. Trexquant Investment LP bought a new position in shares of Coherus Biosciences during the first quarter worth about $319,000. Institutional investors own 64.52% of the company's stock.
In recent action, Coherus Biosciences, Inc. The Company is engaged in the business of developing and commercializing biosimilar products.
What Trump says Comey told him about being cleared
McCabe also pointed out the remarkable nature of Trump's version of his conversations with Comey. But mounting evidence suggests Comey was actually fired because of the Russian Federation probe.
- Derek Jeter gives emotional speech as Yankees retire No. 2 jersey
- Spurs see off Man U in White Hart Lane finale
- Google officially launches Google Assistant for iPhone
- Wannacry crisis: hits over 40000 Indian computers
- Finance ministers seek ways to make growth help more people
- TPK hikes 3D Touch price for iPhone with OLED, says paper
- Judge declares Prince's 6 siblings the heirs to his estate
- Google VR Headsets Will Be Untethered And Fully Tracked
- Soldiers, officer injured by assailant at Milan station
- Election 2017: Nicola Sturgeon wants seat at Brexit talks table